Core Viewpoint - The article discusses the recent court ruling regarding a lawsuit against Longli Biological Technology Co., Ltd. (龙力生物), highlighting the financial implications for Guolian Minsheng Securities Co., Ltd. (国联民生) and its subsidiary, Guolian Minsheng Securities Underwriting and Sponsorship Co., Ltd. [2][5][10] Group 1: Lawsuit Overview - The lawsuit involves 1,618 investors claiming a total of 274.98 million yuan in damages due to false statements made by Longli Biological [5][12] - The court ruled that Guolian Minsheng Securities Underwriting and Sponsorship is liable for 5% of the damages, amounting to approximately 13.75 million yuan [5][9] - The case is currently in the first instance stage, with the possibility of appeal by either party [6][10] Group 2: Financial Impact - The lawsuit's financial implications are not expected to significantly affect the current or future profits of Guolian Minsheng, as the company maintains a stable financial status [10] - The total amount claimed by the plaintiffs includes investment losses, notification fees, and legal fees, with specific amounts detailed for each category [7][12] - The court also ordered the defendants to bear the litigation costs, which total approximately 1.41 million yuan, with Guolian Minsheng responsible for 5% of this amount [9][12] Group 3: Company Background - Longli Biological was listed on the Shenzhen Stock Exchange in July 2011 but faced significant financial difficulties, leading to its stock being suspended in May 2019 and ultimately delisted in July 2020 [3][4] - The company has been under scrutiny due to consecutive years of negative net assets and unqualified audit reports [3][4]
判赔2.75亿!连带赔偿责任会所承担30%,券商5%!
梧桐树下V·2025-08-27 07:36